• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

LDL 累积暴露假说:证据与实际应用。

The LDL cumulative exposure hypothesis: evidence and practical applications.

机构信息

DeepCausalAI Institute for Clinical Translation, Cambridge, UK.

TIMI Study Group, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, USA.

出版信息

Nat Rev Cardiol. 2024 Oct;21(10):701-716. doi: 10.1038/s41569-024-01039-5. Epub 2024 Jul 5.

DOI:10.1038/s41569-024-01039-5
PMID:38969749
Abstract

The trapping of LDL and other apolipoprotein B-containing lipoproteins within the artery wall causes atherosclerosis. As more LDL becomes trapped within the artery wall over time, the atherosclerotic plaque burden gradually increases, raising the risk of an acute cardiovascular event. Therefore, the biological effect of LDL on the risk of atherosclerotic cardiovascular disease (ASCVD) depends on both the magnitude and duration of exposure. Maintaining low levels of LDL-cholesterol (LDL-C) over time decreases the number of LDL particles trapped within the artery wall, slows the progression of atherosclerosis and, by delaying the age at which mature atherosclerotic plaques develop, substantially reduces the lifetime risk of ASCVD events. Summing LDL-C measurements over time to calculate cumulative exposure to LDL generates a unique biomarker that captures both the magnitude and duration of exposure, which facilitates the estimation of the absolute risk of having an acute cardiovascular event at any point in time. Titrating LDL-C lowering to keep cumulative exposure to LDL below the threshold at which acute cardiovascular events occur can effectively prevent ASCVD. In this Review, we provide the first comprehensive overview of how the LDL cumulative exposure hypothesis can guide the prevention of ASCVD. We also discuss the benefits of maintaining lower LDL-C levels over time and how this knowledge can be used to inform clinical practice guidelines as well as to design novel primary prevention trials and ASCVD prevention programmes.

摘要

LDL 和其他载脂蛋白 B 脂蛋白被捕获在动脉壁内会导致动脉粥样硬化。随着时间的推移,更多的 LDL 被捕获在动脉壁内,动脉粥样硬化斑块负担逐渐增加,急性心血管事件的风险也随之增加。因此,LDL 对动脉粥样硬化性心血管疾病 (ASCVD) 风险的生物学效应取决于暴露的程度和持续时间。随着时间的推移,保持 LDL 胆固醇 (LDL-C) 的低水平可以减少被捕获在动脉壁内的 LDL 颗粒数量,减缓动脉粥样硬化的进展,并通过延迟成熟动脉粥样硬化斑块形成的年龄,大大降低 ASCVD 事件的终生风险。对 LDL-C 进行时间总和测量来计算 LDL 暴露的累积量,可产生一个独特的生物标志物,既能反映暴露的程度,又能反映暴露的持续时间,有助于估计任何时间点发生急性心血管事件的绝对风险。将 LDL-C 降低的幅度调至足以使 LDL 的累积暴露量保持在发生急性心血管事件的阈值以下,可以有效地预防 ASCVD。在这篇综述中,我们首次全面概述了 LDL 累积暴露假说如何指导 ASCVD 的预防。我们还讨论了随着时间的推移保持 LDL-C 水平降低的益处,以及如何利用这些知识来为临床实践指南提供信息,以及设计新的一级预防试验和 ASCVD 预防计划。

相似文献

1
The LDL cumulative exposure hypothesis: evidence and practical applications.LDL 累积暴露假说:证据与实际应用。
Nat Rev Cardiol. 2024 Oct;21(10):701-716. doi: 10.1038/s41569-024-01039-5. Epub 2024 Jul 5.
2
Lowering Targeted Atherogenic Lipoprotein Cholesterol Goals for Patients at "Extreme" ASCVD Risk.降低“极高”ASCVD 风险患者的靶向致动脉粥样硬化脂蛋白胆固醇目标。
Curr Diab Rep. 2019 Nov 21;19(12):146. doi: 10.1007/s11892-019-1246-y.
3
Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus Panel.低密度脂蛋白导致动脉粥样硬化性心血管疾病。1. 来自遗传、流行病学和临床研究的证据。欧洲动脉粥样硬化学会共识小组的共识声明。
Eur Heart J. 2017 Aug 21;38(32):2459-2472. doi: 10.1093/eurheartj/ehx144.
4
Effects of weight change on apolipoprotein B-containing emerging atherosclerotic cardiovascular disease (ASCVD) risk factors.体重变化对载脂蛋白 B 所致新兴动脉粥样硬化性心血管疾病(ASCVD)危险因素的影响。
Lipids Health Dis. 2019 Jul 17;18(1):154. doi: 10.1186/s12944-019-1094-4.
5
Prediction of Cumulative Exposure to Atherogenic Lipids During Early Adulthood.成年早期致动脉粥样硬化脂质累积暴露的预测
J Am Coll Cardiol. 2024 Sep 10;84(11):961-973. doi: 10.1016/j.jacc.2024.05.070.
6
Non-HDL-cholesterol and apolipoprotein B compared with LDL-cholesterol in atherosclerotic cardiovascular disease risk assessment.非高密度脂蛋白胆固醇和载脂蛋白 B 与 LDL 胆固醇在动脉粥样硬化性心血管疾病风险评估中的比较。
Pathology. 2019 Feb;51(2):148-154. doi: 10.1016/j.pathol.2018.11.006. Epub 2018 Dec 27.
7
Optimizing Dyslipidemia Management for the Prevention of Cardiovascular Disease: a Focus on Risk Assessment and Therapeutic Options.优化血脂异常管理以预防心血管疾病:关注风险评估和治疗选择。
Curr Cardiol Rep. 2019 Aug 5;21(9):110. doi: 10.1007/s11886-019-1175-z.
8
Total cholesterol/HDL-cholesterol ratio discordance with LDL-cholesterol and non-HDL-cholesterol and incidence of atherosclerotic cardiovascular disease in primary prevention: The ARIC study.总胆固醇/高密度脂蛋白胆固醇比值与 LDL-胆固醇和非高密度脂蛋白胆固醇不相符与一级预防中的动脉粥样硬化性心血管疾病发病的关系:ARIC 研究。
Eur J Prev Cardiol. 2020 Oct;27(15):1597-1605. doi: 10.1177/2047487319862401. Epub 2019 Jul 10.
9
Impact of clonal haematopoiesis on atherosclerotic cardiovascular disease according to low-density lipoprotein cholesterol levels in general population.一般人群中低密度脂蛋白胆固醇水平与克隆性造血对动脉粥样硬化性心血管疾病的影响。
Eur J Prev Cardiol. 2024 Jul 23;31(9):1162-1171. doi: 10.1093/eurjpc/zwae055.
10
A Critical Review of the Consensus Statement from the European Atherosclerosis Society Consensus Panel 2017.对 2017 年欧洲动脉粥样硬化学会共识小组共识声明的批判性评价。
Pharmacology. 2018;101(3-4):184-218. doi: 10.1159/000486374. Epub 2018 Jan 19.

引用本文的文献

1
Functional interaction between immune checkpoints and lipid metabolism in the development of arteriosclerosis obliterans.免疫检查点与脂质代谢在闭塞性动脉硬化发展中的功能相互作用。
Front Immunol. 2025 Sep 1;16:1665454. doi: 10.3389/fimmu.2025.1665454. eCollection 2025.
2
Triglycerides as Determinants of Global Lipoprotein Derangement: Implications for Cardiovascular Prevention.甘油三酯作为全球脂蛋白紊乱的决定因素:对心血管预防的意义。
Int J Mol Sci. 2025 Aug 26;26(17):8284. doi: 10.3390/ijms26178284.
3
Effect of GLP-1RA on coronary progression and cardiovascular outcomes in type 2 diabetic patients after PCI: a prospective cohort study.

本文引用的文献

1
Age-dependent sex differences in cardiometabolic risk factors.心脏代谢危险因素中的年龄依赖性性别差异。
Nat Cardiovasc Res. 2022 Sep;1(9):844-854. doi: 10.1038/s44161-022-00131-8. Epub 2022 Sep 12.
2
World Heart Federation Cholesterol Roadmap 2022.世界心脏联合会胆固醇路线图 2022 年版
Glob Heart. 2022 Oct 14;17(1):75. doi: 10.5334/gh.1154. eCollection 2022.
3
Long-Term Evolocumab in Patients With Established Atherosclerotic Cardiovascular Disease.在已确诊动脉粥样硬化性心血管疾病患者中使用长效依洛尤单抗的研究
胰高血糖素样肽-1受体激动剂对2型糖尿病患者PCI术后冠状动脉病变进展及心血管结局的影响:一项前瞻性队列研究
Sci Rep. 2025 Aug 29;15(1):31824. doi: 10.1038/s41598-025-17574-1.
4
The causal effects of remnant cholesterol on increased risk of cardiovascular diseases in East Asians.残余胆固醇对东亚人心血管疾病风险增加的因果效应。
BMC Med. 2025 Aug 26;23(1):495. doi: 10.1186/s12916-025-04329-y.
5
Cardiometabolic risk stratification in pediatric obesity: evaluating the clinical utility of fasting insulin and BMI-SDS.儿童肥胖中的心脏代谢风险分层:评估空腹胰岛素和BMI-SDS的临床效用。
Cardiovasc Diabetol. 2025 Aug 8;24(1):324. doi: 10.1186/s12933-025-02882-7.
6
Hepatic Lipoprotein Metabolism: Current and Future In Vitro Cell-Based Systems.肝脏脂蛋白代谢:当前和未来基于细胞的体外系统
Biomolecules. 2025 Jul 2;15(7):956. doi: 10.3390/biom15070956.
7
Human Genetics Informing Drug Development in Cardiovascular Disease: Interleukin-6 Signaling as a Case Study.人类遗传学为心血管疾病药物研发提供信息:以白细胞介素-6信号传导为例的研究
Circ Genom Precis Med. 2025 Aug;18(4):e005103. doi: 10.1161/CIRCGEN.125.005103. Epub 2025 Jul 28.
8
Absolute risk-based versus individualized benefit approaches for determining statin eligibility in primary prevention of cardiovascular diseases in Chinese populations: A modeling study.基于绝对风险与个体化获益方法在中国人群心血管疾病一级预防中确定他汀类药物适用资格的建模研究
PLoS Med. 2025 Jul 22;22(7):e1004556. doi: 10.1371/journal.pmed.1004556. eCollection 2025 Jul.
9
Impact of triglyceride glucose-weight adjusted waist index and its cumulative exposure on stroke risk: a nationwide prospective cohort study.甘油三酯葡萄糖-体重校正腰围指数及其累积暴露对卒中风险的影响:一项全国性前瞻性队列研究
Lipids Health Dis. 2025 Jul 17;24(1):243. doi: 10.1186/s12944-025-02667-7.
10
Eosinophil counts predict 3-year risk of major adverse cardiovascular and cerebrovascular events in carotid artery stenosis patients.嗜酸性粒细胞计数可预测颈动脉狭窄患者发生重大心血管和脑血管不良事件的3年风险。
Sci Rep. 2025 Jul 1;15(1):20939. doi: 10.1038/s41598-025-06350-w.
Circulation. 2022 Oct 11;146(15):1109-1119. doi: 10.1161/CIRCULATIONAHA.122.061620. Epub 2022 Aug 29.
4
Distribution of Coronary Artery Calcium by Age, Sex, and Race Among Patients 30-45 Years Old.30-45 岁患者的冠状动脉钙分布按年龄、性别和种族划分。
J Am Coll Cardiol. 2022 May 17;79(19):1873-1886. doi: 10.1016/j.jacc.2022.02.051.
5
Effect of Evolocumab on Coronary Plaque Phenotype and Burden in Statin-Treated Patients Following Myocardial Infarction.依洛尤单抗对心肌梗死后他汀类药物治疗患者的冠状动脉斑块表型和负担的影响。
JACC Cardiovasc Imaging. 2022 Jul;15(7):1308-1321. doi: 10.1016/j.jcmg.2022.03.002. Epub 2022 Mar 16.
6
Beyond 10-Year Risk: A Cost-Effectiveness Analysis of Statins for the Primary Prevention of Cardiovascular Disease.超越 10 年风险:他汀类药物用于心血管疾病一级预防的成本效益分析。
Circulation. 2022 Apr 26;145(17):1312-1323. doi: 10.1161/CIRCULATIONAHA.121.057631. Epub 2022 Mar 7.
7
Association Between Cumulative Low-Density Lipoprotein Cholesterol Exposure During Young Adulthood and Middle Age and Risk of Cardiovascular Events.青年期和中年时期累积低密度脂蛋白胆固醇暴露与心血管事件风险的关系。
JAMA Cardiol. 2021 Dec 1;6(12):1406-1413. doi: 10.1001/jamacardio.2021.3508.
8
Prevalence of Subclinical Coronary Artery Atherosclerosis in the General Population.一般人群中亚临床冠状动脉粥样硬化的患病率。
Circulation. 2021 Sep 21;144(12):916-929. doi: 10.1161/CIRCULATIONAHA.121.055340. Epub 2021 Sep 20.
9
Inclisiran: A Novel Agent for Lowering Apolipoprotein B-containing Lipoproteins.依洛尤单抗:降低载脂蛋白 B 脂蛋白的新型药物。
J Cardiovasc Pharmacol. 2021 Aug 1;78(2):e157-e174. doi: 10.1097/FJC.0000000000001053.
10
Using Mendelian Randomization to Improve the Design of Randomized Trials.应用孟德尔随机化改进随机临床试验设计。
Cold Spring Harb Perspect Med. 2021 Jul 1;11(7):a040980. doi: 10.1101/cshperspect.a040980.